Drugs / ATI-045
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07011706 | May 2025 → Aug 2026 overdue | atopic eczema | Aclaris Therapeutics, Inc. | Active not recruiting | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-03-18 | Aclaris Therapeutics, Inc. | Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis aclaristx.com ↗ |
| 2025-06-02 | Aclaris Therapeutics, Inc. | Aclaris Therapeutics Initiates Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis aclaristx.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ATI-045 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07011706 ↗ |